Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 29th July 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer Ingelheim acquires Global Stem Cell Technology
Jan Spaas, CEO of GST.
Acquisition follows two years of successful partnership. 

Boehringer Ingelheim has acquired Global Stem Cell Technology (GST), a Belgian biotech firm that develops stem cell products for dogs and horses.

The acquisition follows Boehringer Ingelheim's partnership with GST in 2018. In 2019, the companies launched Arti-Cell® Forte in Europe, the first-ever stem cell product in the veterinary sphere granted marketing authorisation by the European Commission.

In a press release, Boehringer Ingelheim states that the acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.

Jean-Luc Michel, Head of Global Strategic Marketing, Boehringer Ingelheim Animal Health, commented: "Collaboration with external partners plays an essential role in helping us expand our portfolio. After two years of a very successful partnership, we have decided to acquire GST. We are convinced that its expertise in the field of state-of-the-art stem cell products will help us bring even more innovative solutions to our customers."

Jan Spaas, CEO of GST added: “Boehringer Ingelheim wants to lead a new wave of innovation in the veterinary field. This ambition is a natural fit with GST’s management, staff and vision. From the very beginning, we aimed to change the veterinary field, a role we will continue to play as a new R&D division within Boehringer Ingelheim,”

The financial terms of the deal have not been disclosed. 

Become a member or log in to add this story to your CPD history

Free CPD announced for BVNA members

News Story 1
 Zoetis is to present a CPD event for free to members of the British Veterinary Nursing Association (BVNA).

Led by veterinary consultant Ruth Moxon, the one-hour online session is designed to help veterinary nurses discuss parasiticide options with clients. It will advise on structuring recommendations, factors for product choice and moving away from 'selling'.

'How do you recommend parasite treatments to your clients?' will be presented on Tuesday, 20 May at 7.30pm. It is free for BVNA members, with 15.00 tickets for non-members.

Veterinary nurses can email cpd@bvna.co.uk to book their place. 

Click here for more...
News Shorts
BBC Radio 4 documentary addresses corporate fees

BBC Radio 4's File on 4 Investigates has released a documentary exploring how corporate-owned veterinary practices may be inflating bills to increase profit.

Released on 15 April, 'What's Happening To Your Vet Bills?' revealed the policies which many corporate groups have in place to increase their profits. This included targets and upgrades which veterinary teams are tasked with meeting on a regular basis.

It also features Anrich Vets, an independently-owned practice based in Wigan. Following the case of Staffordshire terrier Benjy, who is diagnosed with a tumour, the documentary shares how the team were able to offer contextualised care and advice to make the procedure as affordable as possible for his owners.

The documentary can be heard on demand on BBC iPlayer.